Nisha Poddar

Noel Tata, Chairman of Tata Trusts, questioned the legality of N Chandrasekaran's reappointment as Tata Sons chairman, citing procedural concerns from the September 17 board meeting.

The caveats seek to ensure that the trusts are given an opportunity to be heard before the Charity Commissioner passes any order affecting them.

Venu Srinivasan has alleged in a letter to Charity Commissioner that Circular Resolution 107 was meant to stop him voting on Tata Sons listing.

The reorganisation would require a prior no-objection certificate from the RBI, and Tata Trusts are expected to engage with the central bank on the proposed structure.

The company shared the legal opinions in its response to an email from Tata Trusts Chairman Noel Tata questioning the legality of the resolution passed at the Sept. 17 board meeting.

Tata Trusts told NDTV Profit that if these allegations were proven to be true, it will evaluate response and act appropriately.

Companies adopting AI should measure not only efficiency gains but also whether the capacity created is being used to drive innovation and growth, Irina Ghose said.

"HDFC Bank may have communicated the 2 internal candidates' names for CEO to the Reserve Bank of India," the sources informed on the condition of anonymity.

SEBI may need to weigh in as NSE eyes the "permitted to trade" window to list on rival BSE while still trading on its own platform.

The AGM was held against the backdrop of Tata Sons Chairman N Chandrasekaran deciding not to seek another term at the helm of the holding company.

Zepto plans to update its financials and then go back to market to launch its public issue, persons privy to the development said.

In an exclusive interview with NDTV Profit, Sahil Barua said nearly 100% of freight contracts are fuel-cost protected, ruling out any long-term hit to margins from elevated crude oil prices.

Emmer Capital's Raychaudhari outlined the current complex macroeconomic environment where global tech jitters, energy price spikes, and domestic inflation risks are converging to test investor resilience.

Temasek's Lambah noted that investment momentum remains strictly on track, with plans to deploy approximately $10 billion in India

Promoter holding rose from 49.52% in March to 50% at the end of June after purchases during the first quarter.

In an exclusive interview to NDTV Profit, Biocon founder, Kiran Mazumdar-Shaw, also said that insulin "will never go away" and defended company's low-margin bet.

In an exclusive interview to NDTV Profit, Kiran Mazumdar-Shaw says biology, not silicon, could solve the data centre crunch.

In an exclusive interview to NDTV Profit, Biocon founder says the CDMO arm strayed from its core strength but is now being rebuilt.

Awiqli cuts basal insulin dosing from seven injections a week to one. Novo Nordisk India MD Vikrant Shrotriya discusses price, access and growth.

The statement was issued in response to a complaint reportedly made to the Charity Commissioner regarding the transfer of Tata Sons shares that took place over three decades ago.